miR-218-5p and Doxorubicin Combination Enhances Anticancer Activity in Breast Cancer Cells through Parkin-Dependent Mitophagy Inhibition

Investigators analyzed the role of mitophagy in the treatment of the most common anticancer drug, doxorubicin, in different models of breast cancer.